Vaccitech changes name to Barinthus Biotherapeutics to highlight strategic evolution into T-cell immunotherapy company targeting chronic infectious diseases, autoimmunity and cancer

Balintus Biotherapeutics

Balintus Biotherapeutics

OXFORD, UK, Nov. 06, 2023 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (Nasdaq: BRNS), formerly Vaccitech plc (Nasdaq: VACC), is a clinical-stage biopharmaceutical company. Pharmaceutical companies developing novel T-cell immunotherapy candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023 (November 10-14) Presenting data from VTP-300 Phase 2 Hepatitis B trial in Boston, MA

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its business focus beyond vaccines. The company expects to begin trading under its new name and ticker symbol (NASDAQ: BRNS) beginning November 7, 2023. As part of the rebrand, the company has also updated its website – for more information, please visit

“Since spinning out from the University of Oxford, the company has continued to evolve and grow. We started as a vaccines company, branching out into influenza vaccines, then co-invented and early-stage development of Vaxzevria, the AstraZeneca/Oxford COVID-19 vaccine, and other preventive vaccines. Developed.” Balintus Biotherapeutics. “Today, the company is focused on developing novel T cell immunotherapy candidates that evolved from initial vaccine research. We believe the ability to direct T cells using our proprietary platform technology provides more Extensive development opportunities and significant potential to ultimately impact patients’ lives. “We are excited to continue this next chapter of the company’s story as Barinthus Biotherapeutics. “

The company’s new name is inspired by the mythical navigator “Barinthus” who guided the British King Arthur on a ship to the Isle of Avalon for treatment when he was injured. The story of this legendary king who was wounded and guided to a place of healing and continues to reside is reflected in our proprietary platforms and technologies designed to guide the immune system in the treatment of infectious diseases, autoimmunity and cancer.

Data Presentation at Liver Meeting:

Latest summary accepted1:

title: Preliminary pharmacodynamics and safety of repeated doses of Imdusiran (AB-729) followed by VTP-300 or placebo in virally suppressed non-cirrhotic chronic hepatitis B (CHB) subjects

author: Yuen MF, Agarwal K, Roberts SK, Lo GH, Hsu CW, Chuang WL, Chen CY, Su PY, Galhenage S, Yang SS, Antoniello D, Thi E, O’Brien S, Bussey L, Medvedeva E, Eley T, Patel D, Varuggs T, Espiritu C, Ganchua S, Iote C, Anderson M, Fortney T, Cloherty G, Evans T, Sims K

1 Clinical collaboration with Arbutus Biopharma Corporation.

Regular abstracts accepted:

Abstract number: 46173

title: A Phase 2b open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimen of VTP-300 in combination with low-dose nivolumab (LDN) for the treatment of chronic hepatitis B infection.

Demo type: oral expression

Meeting: Hepatitis B: New treatments for hepatitis B virus and hepatitis delta virus

Lecture time: Sunday, November 12, 09:15 ET

author: Yuen MF, Chong WL, Avihingsanon A, Lim S, Mukherjee D, Radka K, Bussey l, Evans T, Tait D

Data summary: VTP-300 has previously demonstrated in Phase 1b/2a studies to effectively and sustainably reduce HBsAg in patients with HBV as monotherapy and in combination with LDN. Evaluating repeated dosing of modified vaccinia Ankara (MVA)-HBV and timing of PD-1 inhibitor dosing in patients with chronic hepatitis B is an important component of optimizing VTP-300 treatment regimens, which may be a key component of functional cure regime.

Both presentations will be posted on the Barinthus Biotherapeutics website following their publication at AASLD.

About VTP-300

VTP-300 is an investigational immunotherapy candidate consisting of an initial dose using the ChAdOx platform and a secondary dose using MVA, both encoding multiple hepatitis B antigens, including full-length surface, modified polymerase and core antigen. VTP-300 is the first antigen-specific immunotherapy that has been shown to induce sustained reductions in HBsAg. Barinthus Biotherapeutics is studying VTP-300 in combination with other agents, including siRNA and low-dose anti-PD-1 antibodies, to control infection and balance immunosuppression and hepatic T-cell exhaustion caused by chronic HBV.

About hepatitis B virus (HBV)

It is estimated that more than 300 million people worldwide have chronic hepatitis B, including 2.4 million in the United States and 14 million in Europe, with the highest prevalence in East Asia and Africa. Approximately 820,000 people die each year from HBV and related complications, such as cirrhosis and hepatocellular carcinoma. Due to low HBV diagnosis rates (approximately 10.5%) who are aware of their infection, and strict treatment eligibility guidelines, only 6.6 million (2.2%) people with chronic hepatitis B are receiving treatment, and less than 10% are able to survive with existing therapies Achieve functional healing.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapy candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping people with serious illnesses and their families is a core guiding principle of Barinthus Biotherapeutics. With a broad product pipeline built around four proprietary platform technologies: ChAdOx, MVA, SNAP-TI and SNAP-CI; Barinthus Biotherapeutics is advancing a pipeline of five product candidates spanning diverse therapeutic areas, including: VTP-300, An immunotherapy candidate designed as a potential component of a functional cure for chronic hepatitis B; VTP-200, a non-surgical product candidate targeting persistent high-risk human papillomavirus (HPV); VTP-1000, a an autoimmune drug candidate designed to treat patients with celiac disease using the SNAP-TI platform; VTP-850, a second-generation immunotherapy candidate designed to treat recurrent prostate cancer; VTP-1100, a preclinical cancer drug candidate Aims to use the SNAP-CI platform to treat patients with HPV-related cancers. Barinthus Biotherapeutics’ proven scientific expertise, diverse product portfolio, and focus on pipeline development enable the company to deliver treatments to people living with infectious diseases, autoimmune diseases, and cancer that impact their daily lives. Tremendous influence. For more information, please visit

forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which generally can be identified by the use of the words “may,” “will,” “plans,” “forward-looking,” “encourage,” “believe ”, “potential” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements, express or implied, regarding the Company’s plans and strategies regarding its pipeline and product candidates, including VTP-300 and HBV003 clinical trials, and VTP-300 for the treatment of chronic hepatitis B, and the company’s plans to change its name and ticker symbol. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that could cause actual events or results to differ from those expressed by any forward-looking statement contained There are material differences from or implied in this press release, including, but not limited to, risks and uncertainties related to the success, cost and timing of the Company’s pipeline development activities and planned and ongoing clinical trials, the Company’s ability to execute its strategy capabilities, regulatory developments that companies may not be aware of related to rebranding and name changes, companies’ ability to fund their operations and access capital, global economic uncertainty including disruptions in the banking industry, the conflict in Ukraine, and the conflicts in Israel and Gaza benefits, and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2022, Quarterly Reports on Form 10-Q, and subsequent filings and the U.S. Securities and Exchange Commission. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company expressly disclaims any obligation to publicly update or revise any such statement to reflect any changes in expectations or events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those stated. forward-looking statements.

Infrared contact:
Christopher M. Calabrese
managing Director
life sciences consultant
+1 917-680-5608

Kevin Gardner
managing Director
life sciences consultant
+1 617-283-2856

Media contact information:
Audra Freese
Sam Brown Company
+1 917-519-9577

Company contact information:
Jonathan Blackburn
Investor Relations and Public Relations Manager
Balintus Biotherapeutics

Source link

Leave a Comment